JP2018515507A5 - - Google Patents

Download PDF

Info

Publication number
JP2018515507A5
JP2018515507A5 JP2017558374A JP2017558374A JP2018515507A5 JP 2018515507 A5 JP2018515507 A5 JP 2018515507A5 JP 2017558374 A JP2017558374 A JP 2017558374A JP 2017558374 A JP2017558374 A JP 2017558374A JP 2018515507 A5 JP2018515507 A5 JP 2018515507A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
alzheimer
composition according
disease
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017558374A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515507A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/030704 external-priority patent/WO2016182812A1/en
Publication of JP2018515507A publication Critical patent/JP2018515507A/ja
Publication of JP2018515507A5 publication Critical patent/JP2018515507A5/ja
Pending legal-status Critical Current

Links

JP2017558374A 2015-05-08 2016-05-04 アルツハイマー病の処置のための神経細胞ストア作動性カルシウム流入経路の活性化方法 Pending JP2018515507A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562159083P 2015-05-08 2015-05-08
US62/159,083 2015-05-08
PCT/US2016/030704 WO2016182812A1 (en) 2015-05-08 2016-05-04 Activation of neuronal store-operated calcium entry pathway for the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2018515507A JP2018515507A (ja) 2018-06-14
JP2018515507A5 true JP2018515507A5 (https=) 2019-06-13

Family

ID=57248333

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017558374A Pending JP2018515507A (ja) 2015-05-08 2016-05-04 アルツハイマー病の処置のための神経細胞ストア作動性カルシウム流入経路の活性化方法

Country Status (6)

Country Link
US (1) US20180147206A1 (https=)
JP (1) JP2018515507A (https=)
KR (1) KR20180004242A (https=)
CN (1) CN107835688A (https=)
HK (1) HK1250658A1 (https=)
WO (1) WO2016182812A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110759985B (zh) * 2018-07-27 2021-11-09 中国人民解放军军事科学院军事医学研究院 一种用于微波辐射致神经元钙信号调节的生物标志物Orai2蛋白
RU2676100C1 (ru) * 2018-10-05 2018-12-26 федеральное государственное автономное образовательное учреждение высшего образования "Санкт-Петербургский политехнический университет Петра Великого" (ФГАОУ ВО "СПбПУ") Применение производных пиперазина для лечения болезни Альцгеймера и деменций альцгеймеровского типа с нарушенной внутриклеточной кальциевой сигнализацией
CN116059192B (zh) 2019-11-13 2024-10-29 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2369967A1 (en) * 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methods of treating nuclear factor-kappa b mediated diseases and disorders
PH12012500097A1 (en) * 2009-07-21 2011-01-27 Shanghai Inst Organic Chem Potent small molecule inhibitors of autophagy, and methods of use thereof
US8598344B2 (en) * 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof
US9393244B2 (en) * 2013-03-15 2016-07-19 Georgetown University Increasing parkin activity by administering a deubiquitinating enzyme inhibitor

Similar Documents

Publication Publication Date Title
ES2995737T3 (en) Compound for use in treating conditions related to the s1p1 receptor
JP2023040106A (ja) 統合的ストレス経路のプロドラッグ調節剤
CN111770914B (zh) 作为神经激肽-1受体拮抗剂的化合物及其用途
RU2762193C2 (ru) Применение антагонистов рецептора ep4 для лечения nash-ассоциированного рака печени
US9447040B2 (en) Tricyclic compounds, compositions comprising them and uses thereof
JP2014518848A (ja) 糖尿病を治療するための選択的アンドロゲン受容体調節因子
JP2010523683A (ja) 糖尿病を治療するための選択的アンドロゲン受容体モジュレータ
CN106999462B (zh) 包含选择性s1p1受体激动剂的药物组合物
EP3331851A1 (en) Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof
TW201625268A (zh) 包含阿茲海默症之治療劑的有關神經細胞之軸索功能不全之疾患之治療劑
BR112020016500A2 (pt) Agente preventivo ou terapêutico e composição farmacêutica para doença inflamatória ou doença óssea
EA202190586A1 (ru) N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, приемлемые в качестве ингибиторов ccr6
JP2024096962A (ja) ポネシモドを含有する医薬的組み合わせ
JP2016516792A (ja) α−２アドレノレセプターおよびシグマレセプターリガンドの組み合わせ物
JP2021534160A5 (https=)
JP2018515507A5 (https=)
KR20190061027A (ko) 비-알코올성 지방간 질환의 치료를 위한 약학 조성물 및 방법
JP2007510737A (ja) 癌処置のためのセラミド異化阻害剤としてのｐｐｍｐ
CA2753330A1 (en) Uses of nk receptor antagonists
JP2016537432A5 (https=)
ES2989178T3 (es) Inhibidores de la producción de prostaglandina D2 como agentes preventivos y terapéuticos para la sarcopenia
WO2016049595A1 (en) Heteroaryl inhibitors of pde4
EP3654959A2 (en) Compositions and methods for treatment of central nervous system tumors
CN114555577A (zh) 用于治疗门静脉炎症和纤维化的噻吩衍生物
CN109939116B (zh) Rock2抑制剂在制备药物中的用途